Preclinical evidence also indicated a more suppressive environment featured excessive myeloid suppressor cells, tumor-associated macrophages (TAMs), and tumor CCL2 secretion after incomplete RFA, which in turn hindered the anti-PD-1 immunotherapy [121]. Here, CCL2 is linked to neoplasm.